TMDX Company Profile and Key Details

TMDX has shown sold momentum, gaining 5.4% over the past week and 20.66% over the past quarter, though year-to-date performance is up 16.67%. Short-term trend indicators are bearishly aligned (SMA20 0.42%, SMA50 1.3%, SMA200 7.31%). The stock’s 14-day RSI is 50.39 (neutral), while the ATR of 7.15 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -13.74% below its high and over 116.79% above its low. Average 10-day trading volume of 986.28 thousand shares is below the 3-month average of 1.31 million, indicating normal recent market interest.

TransMedics Group, Inc. has 34.09 million shares outstanding. The public float is 32.96 million shares, elevated short interest at 41.68% of float. This equals 8.27 million shares. The short ratio is 7.15 days. Institutional investors hold 113.86% of the float. Insiders own 3.43%. Hassanein Waleed H holds 495.01 thousand shares, TOBIN JAMES R has 173.15 thousand shares and Khayal Tamer I has 36.04 thousand shares. Over the past six months, insider transactions show net selling. They sold 24.50 thousand shares across 7 transactions.

Wall Street analysts project EPS growth of -1.06% annually over the next five years. The latest quarter delivered EPS of $0.30. The next quarter is forecast at $0.66. Next year's EPS is expected at $44.85. Analyst sentiment is bullish. Analyst rating data shows there are 7 Strong Buy ratings, 11 Buy ratings, 8 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $175.00 to $75.00. The high target offers 137.03% upside. The low target suggests 1.58% downside. The mean target is $135.69. This offers 83.79% upside. TransMedics Group, Inc. earnings surprise history is a mixed track record. The quarter that ended May 05, 2026, missed forecasts by -51.61%. The prior quarter beat by 39.02%. Over the last six quarters, Apple has recorded several small beats. These include -13.64% in February 27, 2025.

TransMedics Group, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.09. This means the shares are trading below this model’s fair value.

TransMedics Group, Inc. (NASDAQ:TMDX) closed at $73.83 USD, losing -$1.68 (-2.22%) from the previous close of $75.51. The stock is currently mid-range between its 52-week high and low $60.10 and $156.00. With a market capitalization of about $2.55 billion, TransMedics Group, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~1.88). Key stats such as the average daily volume over the past year has been around 1.30 million shares, volume is running light vs its 52-week average. Headquartered in Andover, MA, TransMedics Group, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Waleed H. Hassanein, the company employs approximately 728 people and listed since May 02, 2019. TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure.

TransMedics Group, Inc. trades at a P/E ratio of 14.72, slightly below the S&P 500 average, with a price-to-sales ratio of 4.02 and a price-to-book ratio of 5.15 trading at moderately above to book value. The P/FCF stands at 16.91, also above market averages.

Our AI price prediction model suggests that TransMedics Group, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.1%, with price expected at $73.02 by July 06, 2026, within a range of $61.13 to $84.70 3-Month Outlook: Projected fall of -64.31%, reaching $26.35 by September 18, 2026, with a range of $22.96 to $29.78. 1-Year Outlook: Projected gain of 24.5%, with price at $91.92 by June 22, 2027, within a range of $80.71 to $103.10.

TransMedics Group, Inc. (NASDAQ:TMDX) shares are up 16.67% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows TransMedics Group, Inc. trading at a premium to the broader market with a P/E of 14.72. Analyst sentiment is mixed, with the majority of ratings in Hold territory and a mean price target of $122.80, suggesting 66.33% upside. Our AI forecast model points to short-term weakness (-1.1% over two weeks), a medium-term fall (-64.31% over three months), and a longer-term gain (24.5% over one year), with expected trading ranges indicating moderate volatility.